Neurogene Inc. (NGNE) Live Share Price, Invest From India

Neurogene Inc. Stock Performance

as on July 7, 2026 at 6:59 am IST

Day's Low
Day's High
$32.51
Day's Price Range
$36.03
$32.45
-0.18%
Downside
11.03%
Upside
52 Week's Low
52 Week's High
$15.93
52-Week Price Range
$37.27
$32.45
50.91%
Downside
14.84%
Upside

Neurogene Inc. share price movements today

Previous Close: $35.34
Open: $35.14
Volume: 229.8K
Day's Low - High: $32.51 - $36.03
52 Week Low - High: $15.93 - $37.27

Neurogene Inc. Historical Returns

1 Month Return: + 33.41 %
3 Month Return: + 72.64 %
1 Year Return: + 75.91 %
3 Year Return: 0 %
5 Year Return: 0 %

Neurogene Inc. Stock Fundamentals & Key Indicators

Check Neurogene Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$704.2M

EPS (TTM)

-5.3133

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-107.5M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-37.25%

Neurogene Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neurogene Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Neurogene Inc.	BUY	$704.2M	NA	NA	0.00%	NA
Revolution Medicines Inc.	BUY	$40.2B	501.91%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$41.8B	79.37%	78.79	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$134.0B	163.95%	31.36	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$68.6B	12.37%	15.97	29.65%	0.5700000000000001%

Stock Returns calculator for Neurogene Inc. Stock including INR - Dollar returns

The Neurogene Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Neurogene Inc. investment value today

Current value as on today

₹1,79,670

Returns

₹79,670

(+79.67%)

Returns from Neurogene Inc. Stock

₹61,523 (+61.52%)

Dollar Impact

₹18,147 (+18.15%)

Analyst Recommendation on Neurogene Inc. Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.91% of analysts recommend a 'BUY' rating for Neurogene Inc.. Average target price of $81

Neurogene Inc. Share Price Target

Get share price movements and forecasts by analysts on Neurogene Inc..

What analysts predicted

59.94%UPSIDE

Target Price

$81

Current Price

$32.45

Analyzed by

11 Analysts

Target

$81.00

Neurogene Inc. target price $81, a slight upside of 59.94% compared to current price of $32.45. According to 11 analysts rating.

Indian Investors' Interest in Neurogene Inc. Stock

Search interest for Neurogene Inc. Stock has decreased by -25% in the last 30 days, reflecting a downward trend in search activity.

Time period: June 7, 2026 to July 7, 2026

Change:-25% versus previous 30 day period

Neurogene Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	0	-	0	-	-	-	-	-
Gross Profit	-12	0	0	0	-15	-17	-19	-17	0	0
Operating Income	-14	-18	-20	-22	-21	-25	-26	-23	-27	-33
EBITDA	3	-16	-17	-19	-18	-21	-21	-20	-23	-30
Interest Expense	0	0	0	0	0	0	0	0	0	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	2	-16	-18	-20	-19	-22	-22	-20	-24	-30
Income Tax Expense	1	0	0	-	-	-	-	-	-	-
Net Income	2	-16	-18	-20	-19	-22	-22	-20	-24	-30
Net Profit Margin	0.00%	0.00%	-1999.14%	0.00%	2109.62%	0.00%	0.00%	0.00%	0.00%	0.00%

Neurogene Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2021	Jun 2022	Dec 2022	Jun 2023	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	-	0	-
Gross Profit	-42	-	-3	-	-3	-2	-3
Operating Income	-50	-	-56	-	-55	-82	-103
EBITDA	-49	-	-51	-	-33	-71	-87
Interest Expense	-	-	0	-	0	0	0
Depreciation	0	-	3	-	3	3	3
Income Before Tax	-50	-	-55	-	-36	-75	-90
Income Tax Expense	0	-	0	-	0	-	-
Net Income	-50	-50	-55	-55	-36	-75	-90
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	-8123.68%	0.00%

Neurogene Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-16	-18	-20	-19	-22	-22	-20	-24	-30
Operating Cash Flow	-21	-15	-15	-17	-20	-19	-19	-16	-26
Investing Cash Flow	29	-23	-28	-102	-45	7	22	29	46
Financing Cash Flow	-6	0	0	190	0	0	9	20	0
Change in Cash	1	-39	-44	69	-65	-11	12	32	20

Neurogene Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-50	-31	-8	-33	-50	-55	-36	-75	-90
Operating Cash Flow	-44	-31	-15	-24	-46	-52	-51	-70	-77
Investing Cash Flow	64	55	0	-2	-18	-2	25	-125	14
Financing Cash Flow	0	0	82	77	51	66	92	184	30
Change in Cash	19	24	66	49	-13	11	66	-11	-32

Global Institutional Holdings in Neurogene Inc.

Funds	Holdings
Trails Edge Capital Partners, LP	4.95%
Balyasny Asset Management LLC	4.55%
Citadel Advisors Llc	2.45%
Millennium Management LLC	1.31%
Casdin Capital, LLC	8.99%

See all

Insights on Neurogene Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 3 Years
In the last 3 years, NGNE has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Price Rise
In the last 7 days, NGNE stock has moved up by 12.4%
NO EFFECT
Against Peers
In the last 1 year, Revolution Medicines, Inc. Common Stock has given 416.1% return, outperforming this stock by 334.9%

About Neurogene Inc.

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.

Organisation	Neurogene Inc.
Headquarters	535 W 24th Street, New York, NY, United States, 10011
Industry	Biotechnology
CEO	Dr. Rachel L. McMinn Ph.D.
E-voting on shares	Click here to vote

Key Management of Neurogene Inc.

Name	Title
Dr. Stuart Cobb Ph.D.	Chief Scientific Officer
Ms. Donna M. Cochener-Metcalfe J.D., L.L.M.	Senior VP, General Counsel & Corporate Secretary
Mr. Ricardo Jimenez	Senior Vice President of Technical Operations
Mr. Arvind Sreedharan	Senior Vice President of Business Operations
Ms. Christine Mikail Cvijic J.D.	President, CFO & Director
Dr. Julie Jordan M.D.	Chief Medical Officer
Ms. Christina Shafer	Chief Commercial Officer
Dr. Rachel L. McMinn Ph.D.	Founder, Executive Chair & CEO
Dr. Andrew E. Mulberg CPI, FAAP, M.D.	Senior VP of Regulatory Affairs, Quality Assurance & Quality Control

FAQs

What is Neurogene Inc. share price today?

Neurogene Inc. share price today is $32.45 as on July 7, 2026 at 1:29 am IST at the close of the market. Neurogene Inc. share today touched a day high of $36.03 and a low of $32.51.

What is the 52 week high and 52 week low for Neurogene Inc. share?

Neurogene Inc. share touched a 52 week high of $37.27 on October 16, 2025 and a 52 week low of $15.93 on February 5, 2026. Neurogene Inc. stock price today i.e. July 7, 2026 at 1:29 am IST is closed at $32.45,which is 12.92% down from its 52 week high and 103.70% up from its 52 week low.

What is Neurogene Inc.'s market capitalisation today?

Neurogene Inc. market capitalisation is $0.00T as on July 7, 2026 at 1:29 am IST.

How to invest in Neurogene Inc. Stock (NGNE) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Neurogene Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neurogene Inc. Shares that will get you 0.0462 shares as per Neurogene Inc. share price of $32.45 per share as on July 7, 2026 at 1:29 am IST.

What is the minimum amount required to buy Neurogene Inc. Stock (NGNE) from India?

Indian investors can start investing in Neurogene Inc. (NGNE) shares with as little as ₹95.395 or $1 (as of July 7, 2026 at 7:37 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹953.95 in Neurogene Inc. stock (as per the Rupee-Dollar exchange rate as on July 7, 2026 at 7:37 am IST). Based on Neurogene Inc. share’s latest price of $32.45 as on July 7, 2026 at 1:29 am IST, you will get 0.3082 shares of Neurogene Inc.. Learn more about fractional shares .